Cetuximab/avelumab

Phase 2

MERCK (MRK)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Q3 '27

MRKPhase 2$364.4B

Cetuximab/avelumab Phase 2 Est. Readout (AVEC-119)

Cetuximab/avelumab• Head and Neck Squamous Cell Carcinoma (HNSCC)67

Q3 2027~QEstimated

CT.gov

00%

Competitive Landscape

0 competitors in Head and Neck Squamous Cell Carcinoma (HNSCC)

View Full Landscape

Drug Information

Target Indication

Head and Neck Squamous Cell Carcinoma (HNSCC)

Clinical Trial

NCT06869473

Last updated: 11/4/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

MRK

MERCK

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

SevofluranePhase 3

Muscle Relaxation

HIBERIX™Phase 3

Pneumococcal Infections

ElbasvirPhase 3

Hepatitis C

DecadronPhase 3

Malignant Neoplasms of Male Genital Organs

Pentacel™Phase 3

Pneumococcal Infections

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts